CamAPS FX is an artificial pancreas app which aims to help manage glucose levels in people with type 1 diabetes, aged one year and older, using a hybrid closed-loop approach.
The user has the option of easing off or boosting therapy as physiological demands require, such as during exercise. The app runs on a standard Android smartphone and feeds data to the cloud so that health care professionals and loved ones including parents can see their children’s levels at any time on their phones.
Developed by CamDiab at the University of Cambridge, trials have shown a significant increase in glucose time in range and improved quality of life, as well as a reduction in time spent in hypoglycaemia and hyperglycaemia. An Eastern AHSN commissioned health economic assessment also demonstrated a potential cost saving of £3.2m per year for healthcare in the UK. We are now supporting the roll out of this innovation across the NHS.
Visit the CamDiab website now.